GSK and LTZ Form Strategic Collaboration to Advance Novel Myeloid Cell Engagers in Oncology
Friday, November 21, 2025
GSK plc and LTZ Therapeutics, an immunotherapy-focused biotechnology company in Redwood City, California, have entered a strategic research collaboration to develop a new class of cancer treatments known as myeloid cell engagers (MCEs). The partnership will focus on creating up to four first-in-class MCE therapies for both blood cancers and solid tumours. Under the agreement, GSK will have an exclusive option to license global development and commercial rights for these pre-clinical candidates.
MCEs are emerging immuno-oncology therapies designed to activate the body’s immune system to detect and kill tumour cells. Myeloid cells form a large proportion of tissue-resident immune cells, giving them strong potential to infiltrate and target tumours effectively. LTZ’s MCE platform has produced encouraging pre-clinical results across several tumour types. Unlike some existing approaches that may require hospital monitoring due to safety concerns, MCEs aim to deliver effective anti-tumour activity with a more manageable safety profile suitable for community-based treatment.
The collaboration supports GSK’s ongoing investment in next-generation cancer technologies and aims to accelerate the development of innovative immune-engaging therapies. LTZ views this agreement as an important step in advancing treatments based on myeloid biology to address areas of high unmet medical need.
Together, GSK and LTZ aim to progress novel MCE therapies that could expand future options for people living with cancer.
Source: gsk.com
